1.1.1.88: hydroxymethylglutaryl-CoA reductase
This is an abbreviated version!
For detailed information about hydroxymethylglutaryl-CoA reductase, go to the full flat file.
Word Map on EC 1.1.1.88
-
1.1.1.88
-
cholesterol
-
statin
-
lipoprotein
-
simvastatin
-
sterol
-
low-density
-
coronary
-
cardiovascular
-
lovastatin
-
hypercholesterolemia
-
pravastatin
-
atorvastatin
-
lipid-lowering
-
cholesterol-lowering
-
3-hydroxy-3-methylglutaryl-coa
-
cerivastatin
-
mevinolin
-
alpha-hydroxylase
-
statin-induced
-
compactin
-
mevalonolactone
-
cholestyramine
-
mevalonii
-
lipoprotein-deficient
-
medicine
-
25-hydroxycholesterol
-
fibric
- 1.1.1.88
- cholesterol
- statin
- lipoprotein
- simvastatin
- sterol
-
low-density
- coronary
- cardiovascular
- lovastatin
- hypercholesterolemia
- pravastatin
- atorvastatin
-
lipid-lowering
-
cholesterol-lowering
- 3-hydroxy-3-methylglutaryl-coa
- cerivastatin
- mevinolin
-
alpha-hydroxylase
-
statin-induced
- compactin
- mevalonolactone
- cholestyramine
- mevalonii
-
lipoprotein-deficient
- medicine
- 25-hydroxycholesterol
-
fibric
Reaction
Synonyms
3-hydroxy-3-methylglutaryl CoA reductase 1, 3-hydroxy-3-methylglutaryl coenzyme A reductase, 3-hydroxy-3-methylglutaryl-CoA reductase, 3-hydroxy-3-methylglutaryl-coenzyme-A reductase, beta-hydroxy-beta-methylglutaryl CoA-reductase, beta-hydroxy-beta-methylglutaryl coenzyme A reductase, HMG-CoA reductase, HMGCoAR, HMGR, hydroxymethylglutaryl coenzyme A reductase, Mt HMGR1, mvaA, NADH-dependent HMG-CoA reductase, NADH-HMGR
ECTree
Advanced search results
Inhibitors
Inhibitors on EC 1.1.1.88 - hydroxymethylglutaryl-CoA reductase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
(3S,6Z)-3-benzyl-1-(4-fluorobenzyl)-8-(4-methoxyphenyl)-4-(3-methylbutanoyl)-3,4,5,8-tetrahydro-1,4-diazocin-2(1H)-one
(3S,6Z)-3-benzyl-1-(4-fluorobenzyl)-8-(4-methoxyphenyl)-4-[[(E)-2-phenylethenyl]sulfonyl]-3,4,5,8-tetrahydro-1,4-diazocin-2(1H)-one
(3S,6Z)-3-benzyl-4-(3,3-dimethylbutanoyl)-1-(4-fluorobenzyl)-8-(4-methoxyphenyl)-3,4,5,8-tetrahydro-1,4-diazocin-2(1H)-one
(3S,6Z)-4-(biphenyl-4-ylsulfonyl)-1-(4-fluorobenzyl)-8-(4-methoxyphenyl)-3-methyl-3,4,5,8-tetrahydro-1,4-diazocin-2(1H)-one
citrate
-
competitive inhibition with respect to 3-hydroxy-3-methylglutaryl-CoA
lovastatin
-
pharmacological inhibition of HMGR activities decreases nodule number and delays nodulation
simvastatin
-
treatment prevents endotoxemic liver injury by inhibiting leukocyte infiltration and hepatocellular apoptosis. The protective effects are dependent on the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway
(3S,6Z)-3-benzyl-1-(4-fluorobenzyl)-8-(4-methoxyphenyl)-4-(3-methylbutanoyl)-3,4,5,8-tetrahydro-1,4-diazocin-2(1H)-one
-
purified enzyme, 52.6% residual activity at 0.01 mM
(3S,6Z)-3-benzyl-1-(4-fluorobenzyl)-8-(4-methoxyphenyl)-4-(3-methylbutanoyl)-3,4,5,8-tetrahydro-1,4-diazocin-2(1H)-one
-
antiproliferative activity in L-1210 cell, IC50 0.00148 mM
(3S,6Z)-3-benzyl-1-(4-fluorobenzyl)-8-(4-methoxyphenyl)-4-[[(E)-2-phenylethenyl]sulfonyl]-3,4,5,8-tetrahydro-1,4-diazocin-2(1H)-one
-
purified enzyme, 32.3% residual activity at 0.01 mM
(3S,6Z)-3-benzyl-1-(4-fluorobenzyl)-8-(4-methoxyphenyl)-4-[[(E)-2-phenylethenyl]sulfonyl]-3,4,5,8-tetrahydro-1,4-diazocin-2(1H)-one
-
antiproliferative activity in L-1210 cell, IC50 0.0023 mM
(3S,6Z)-3-benzyl-4-(3,3-dimethylbutanoyl)-1-(4-fluorobenzyl)-8-(4-methoxyphenyl)-3,4,5,8-tetrahydro-1,4-diazocin-2(1H)-one
-
purified enzyme, 43.4% residual activity at 0.01 mM
(3S,6Z)-3-benzyl-4-(3,3-dimethylbutanoyl)-1-(4-fluorobenzyl)-8-(4-methoxyphenyl)-3,4,5,8-tetrahydro-1,4-diazocin-2(1H)-one
-
antiproliferative activity in L-1210 cell, IC50 0.00143 mM
(3S,6Z)-4-(biphenyl-4-ylsulfonyl)-1-(4-fluorobenzyl)-8-(4-methoxyphenyl)-3-methyl-3,4,5,8-tetrahydro-1,4-diazocin-2(1H)-one
-
purified enzyme, 54.4% residual activity at 0.01 mM
(3S,6Z)-4-(biphenyl-4-ylsulfonyl)-1-(4-fluorobenzyl)-8-(4-methoxyphenyl)-3-methyl-3,4,5,8-tetrahydro-1,4-diazocin-2(1H)-one
-
antiproliferative activity in L-1210 cell, IC50 0.00119 mM
-
competivive inhibitor vs. mevalonate, non inhibitory vs. NAD+
mevalonate
-
the addition of reaction product results in a dramatic loss of immunoreactive enzyme
-
peptic and tryptic soybean hydrolysates (2.5 mg/ml) inhibit the 3-hydroxy-3-methylglutaryl-CoA reductase activity in Hep-G2 cells by 16% and 76.9%, respectively
-
additional information
-
no inhibition citrate, succinate, glutarate, 3,3-dimethylacrylate, 2,2-dimethylpropionate, acetoacetate
-
additional information
-
no inhibition citrate, succinate, glutarate, 3,3-dimethylacrylate, 2,2-dimethylpropionate, acetoacetate
-